DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
April 30, 2019 16:58 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, April 30, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that Dr Harry Alcorn, its Chief Medical Officer...
DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update
March 19, 2019 16:30 ET
|
DiaMedica Therapeutics Inc.
Dosed first patients in Phase Ib study of DM199 in Chronic Kidney Disease patients under an IND accepted by the FDA in 2018; Plan to initiate Phase II studies in 2H 2019Acute ischemic stroke Phase II...
DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
March 18, 2019 13:56 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 18, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March...
DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019
March 12, 2019 13:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The Ritz...